Behind the Blockbusters: Rare Disease Research Trends

Don Johnston
Senior Marketing Communication Director, Life Sciences
Clarivate Analytics
Richard Harrison
Chief Scientific Officer
Clarivate Analytics

Behind each blockbuster is a story 12 to 15 years in the making. Three of the blockbuster drugs are for rare and orphan diseases. Until recently, the monies raised selling the drug to a small patient population did not cover the development costs and these drugs were rarely developed. This has changed in recent years as now almost a third of drugs currently on the market for rare diseases now generate more than $1B in sales annually.

This talk will focus on:

  • the history of rare and orphan disease research
  • the recent approvals
  • where the field is headed